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Abstract
Background: The electronic health record (EHR) of the general physician (GP) is an important tool that can be used
to assess and improve the quality of healthcare. However, there are some problems when (re) using the data
gathered in the EHR for quality assessments. One problem is the lack of data completeness in the EHR. Audit and
feedback (A&F) is a well-known quality intervention that can improve the quality of healthcare. We hypothesize that
an automated A&F intervention can be adapted to improve the data completeness of the EHR of the GP, more
specifically, the number of correctly registered diagnoses of type 2 diabetes and chronic kidney disease.
Methods: This study is a pragmatic cluster randomized controlled trial with an intervention at the level of GP
practice. The intervention consists of an audit and extended electronically delivered feedback with multiple
components that will be delivered 4 times electronically to general practices over 12 months. The data will be
analyzed on an aggregated level (per GP practice). The primary outcome is the percentage of correctly registered
diagnoses of type 2 diabetes. The key secondary outcome is the registration of chronic kidney disease. Exploratory
secondary outcomes are the registration of heart failure, biometric data and lifestyle habits, and the evolution of 4
different EHR-extractable quality indicators.
Discussion: This cluster randomized controlled trial intends to primarily improve the registration of type 2 diabetes
in the EHR of the GP and to secondarily improve the registration of chronic kidney disease. In addition, the
registration of heart failure, lifestyle parameters, and biometric data in the EHR of the GP are explored together with
4 EHR-extractable quality indicators. By doing so, this study aims to improve the data completeness of the EHR,
paving the way for future quality assessments.
Trial registration: ClinicalTrials.gov NCT04388228. Registered on May 14, 2020.
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Background
The electronic health record (EHR) is an important in-
strument that, when properly implemented, can be used
as a tool to improve the quality of healthcare [1]. How-
ever, many challenges need to be overcome to use the
vast amount of EHR-stored data for quality assessment
[2, 3]. One of these challenges is the lack of data com-
pleteness of the EHR and, in particular, the varying qual-
ity of the correct and complete registration of diagnoses
[4–6]. After all, when the quality of care for certain dis-
eases needs to be evaluated, the number of registered
diagnoses of these diseases in the problem list of the
EHR needs to be as accurate as possible to have reliable
results in our quality measurement. In the past, data
quality feedback tools and frameworks have been devel-
oped to address the problem of the lack of data com-
pleteness [7, 8].
Chronic diseases such as diabetes mellitus type 2
(DM 2) and chronic kidney disease (CKD) have a high
prevalence, and the quality of primary care for these
conditions needs improvement [9, 10]. For example,
CKD can be identified in the EHR with the help of the
electronic CKD phenotype, which has proven to be an
accurate method to detect patients likely to have CKD
based on data stored in the EHR [11]. However, there
is still the need for effective organizational and technical
strategies to achieve data completeness [12]. The elec-
tronic CKD phenotype is thus an important first step,
but additional pragmatic trials to explore implementa-
tion strategies incorporating this electronic CKD pheno-
type are necessary [13]. An implementation strategy
that can be useful for this purpose in primary care
could be audit and feedback (A&F).
Audit and feedback is a well-known quality inter-
vention that, according to the last Cochrane review,
leads to “small but potentially important improve-
ments in professional practice” [14]. However, the im-
portant features of A&F and their influence on the
effect of an A&F intervention are still the subject of
debate [15]. Previous work identified some testable
and theory-informed hypotheses for designing an
A&F intervention, and suggestions to improve the in-
terventions’ effectiveness are available in the literature
[16, 17]. Some features of the feedback are known to
be effective, for example, the frequency of the feed-
back provision (more than once), but other features,
such as the use of benchmarks as a comparison, the
evidence-based quality of the feedback, and a low
cognitive load of the feedback, need further investiga-
tion [14, 16–19]. Therefore, the aim of this study is
to investigate whether an automated A&F interven-
tion, using different features of feedback, can be ef-
fective in improving the data completeness of the
EHR in primary care.
Methods
Study design and objectives
Study design
The study is a pragmatic cluster randomized controlled
trial (CRCT) with a superiority framework and an inter-
vention at the level of the general physician (GP) practice.
The protocol is reported according to the Standard Proto-
col Items: Recommendations for Interventional Trials
(SPIRIT) checklist [20] (see additional file 1 and Fig. 1).
Primary objective
The primary objective of this study is to improve the
quality of registration of DM 2 in GP EHR.
Key secondary objective
 Improve the registration of CKD
Exploratory secondary objectives
 Evaluate the registration of heart failure, biometric
data, and lifestyle habits (smoking, exercise, weight,
height, alcohol use)
 Two different EHR-extractable quality indicators for
DM 2 and two different EHR-extractable quality indi-
cators for CKD will be evaluated to investigate whether
an improved registration of these two diseases has an
impact on EHR-extractable quality indicators.
Study population, eligibility criteria, and data storage
This trial has GP practices as the level of allocation. All
GPs in the Intego network will be asked to participate in
this trial. For GPs working in a group practice, the whole
group will be asked to collaborate. GP practices are ex-
cluded when participation is not unanimous. Intego is a
Belgian general practice-based morbidity registration
network at the Center of General Practice of the Univer-
sity of Leuven [21]. Intego collects data on health pa-
rameters, incidence and prevalence rates, laboratory
results, and prescribed drugs for all relevant subgroups.
As of 2020, 395 GPs of 106 practices spread throughout
Flanders, Belgium, collaborated in Intego. In order to
ensure enough GP practices take part in the trial, all the
GP practices will be contacted and/or visited individually
and asked to take part in this trial. An Intego researcher
will explain the study and request informed consent.
The researcher will also emphasize that the provision of
the feedback is an incentive on its own. Therefore both
groups will receive feedback although the feedback in
the control group will be basic. In addition, the Intego
researcher will also inform the participants that the
intervention will not be intrusive since it will be inte-
grated (automated) in the normal workflow of the GP
(to optimize the use of the EHR-system).
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The inclusion criteria for GP practices participating
in this trial are the same criteria as for inclusion in
the Intego network, which are explained in more de-
tail elsewhere [21, 22]. Only the aggregated data of
patients 40 years or older who had at least one con-
sultation the past year will be analyzed for both pri-
mary and secondary outcomes.
The data will be hosted on the Healthdata.be platform,
which is described in more detail elsewhere [22].
Intervention
The intervention consists of an extended electronic-
ally delivered feedback report with multiple compo-
nents that will be delivered 4 times electronically
Fig. 1 Time schedule. DM 2, diabetes mellitus type 2; CKD, chronic kidney disease; EHR, electronic health record
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into GP practices over 12 months. The extended
feedback report is generated based on an automated
audit that is built into the EHR of the GP. This
audit will be executed on the Intego database in an
automated fashion 4 times and is available in both
the control and intervention groups. The feedback
report for both trial arms will be provided on the in-
dependent Healtstat.be platform. The intervention
group will also receive the extended feedback report
through a push system into their e-health inbox to
minimize the effort to consult it. The aim of the
push system is to involve participating GPs and to
actively direct their attention to the task at hand,
namely, the registration of diagnosis and parameters
in the EHR.
The extended feedback report will be delivered in the
form of action plans and goals consisting of multiple
components:
 Benchmarking of the results of the audit with
peers on disease-specific laboratory results or
medication prescriptions. The results of the audit
will be compared with the mean of the 10% best
performers according to the Achievable Bench-
marks of Care (ABC) method [23].
 A low cognitive load of the feedback, such that the
results will be presented with the help of graphs and
without too many in-depth elements.
 Guidance on which codes to use for which cases or
where to put the information in a structured way.
 Links to disease-specific guidelines.
 A push system to minimize the effort the GP must
make to consult the feedback.
The aim of the automated audit is to identify the un-
registered population, and this built-in audit is available
in both study arms. The aim of the extended feedback
report is to improve the registration level in the EHR
and thus improve the data completeness of the EHR.
The control group will also have access to the auto-
mated audit since it is built in the EHR and will receive
basic feedback on the level of registration in their EHR.
The feedback will only be available on HealtStat.be
through a pull system, so GPs will need to actively check
Healtstat.be. For a detailed comparison of control versus
intervention, please see Table 1.
Allocation concealment and random sequence generation
The list of participating practices will be known at the
start of the trial. The allocation sequence will be per-
formed by a statistician (independent from the research
group) and it will be generated using covariate-based
constrained randomization [24]. More specifically, out of
a list of all acceptable allocations one allocation scheme
will be drawn at random. To balance the mean size of
the practice between both groups, a list of all possible al-
locations (restricted to those allocations with equal num-
ber of practices in each group) with a maximal
difference of 5% in mean number of patients per practice
and a maximal difference of 5% in total number of pa-
tients will be created and one allocation will be drawn at
random from this list [24]. The covariate-based con-
strained randomization procedure will be implemented
using a SAS-macro [25]. If the trial would start before
all practices are known, practices with “late entry” will
be allocated using minimization [26], categorizing the
number of patients per practice into 2 or 3 categories.
The control versus intervention group will be allocated
in a 1:1 manner. GPs are not blinded to the intervention.
The research facility will be blinded to the allocations
until all data are collected.
Table 1 Intego feedback trial: control versus intervention group
Control group Intervention group
Four different feedback moments and reports over
12 months on the following:
- The registration level of DM 2
- The registration level of CKD
- The registration level of lifestyle habits: the
number of patients with lifestyle factors registered
in the EHR; lifestyle factors = smoking, alcohol use,
exercise, weight, height
- The registration level of heart failure
• Diagnostic built-in audit on registration of (parameters of) DM 2, CKD, heart failure and life-
style habits available in the EHR CareConnect®
• Basic feedback available at
Healthstat.be
• Feedback = percentages per
registered diagnosis/parameter per GP
practice in text
• Pull system where the GP needs to
actively check for feedback by logging
in on the website of Healthstat.be
• Extended feedback in the form of action plans
and goals consisting of the following:
o Percentages per registered diagnoses/parameters
per GP practice, presented in graphs with low
cognitive load
o Benchmarking with peers on disease-specific lab
results and/or with the percentage of patients who
receive disease-specific medication (ABC method)
o Guidance on which codes to use for which cases
or where to put the information in a structured
way
o Links to disease-specific guidelines
• Available at Healthstat.be
• Push system to eHealth inbox to minimize the
effort necessary to consult it
DM 2 diabetes mellitus type 2, CKD chronic kidney disease, EHR electronic health record, GP general physician, ABC Achievable Benchmarks of Care method
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Outcomes
Our primary outcome is the registration level of DM 2.
This registration level will be expressed as the percentage
of registered diagnoses of DM 2 in the EHR. The numer-
ator will be the number of registered diagnoses of DM 2
in the EHR, and the denominator will be the number of
patients with a prescription of diabetes medication (ATC
classification A10) or with elevated levels of HbA1c (at
least once > 53mmol/mol) or with abnormal fasting gly-
cemia (2 independent measurements > 126mg/dl). For
the primary outcome, we hypothesize that the interven-
tion can achieve an improvement of 10% points (from
75% to 85%) in registration level within 12months.
As a key secondary outcome, we will focus on the
registration of CKD. The registration of CKD will be
expressed as the percentage of registered CKD diagnoses
in the EHR, with the numerator the number of regis-
tered diagnoses of CKD and the denominator the num-
ber of patients with a decreased (≤ 45 mL/min/1.73 m2)
estimated glomerular filtration rate (eGFR). For the
registration of CKD, we hypothesize the intervention can
achieve an improvement of 20% points (from 50% to
70%) in registration level because preliminary analyses
show the quality of registration of CKD is lower than for
the primary outcome.
As exploratory secondary outcomes, we will evaluate
the registration of heart failure, lifestyle factors (such as
smoking and alcohol use), and biometric data (such as
weight and length), and explore two EHR-extractable
quality indicators for CKD and two for DM 2. The regis-
tration of heart failure will be expressed as the percent-
age of heart failure patients, with the numerator the
number of registered heart failure diagnoses and the de-
nominator the total active patient population older than
40. Lifestyle factors and biometric data will be expressed
as the percentage of patients who have registered life-
style factors or biometric data in their EHR.
The EHR-extractable quality indicators we will explore
are as follows [27, 28]:
– Percentage of patients with CKD, in whom the GFR,
albuminuria, and total protein is determined at least
once a year
– Percentage of patients with CKD who are vaccinated
with a pneumococcal vaccine
– Percentage of patients with DM 2 and an eGFR of <
30 mL/min/1.73 m2 who no longer receive
metformin.
– Percentage of patients with DM 2 whose HbA1c
level is measured at least once every 6 months
Ethical approval
The Intego procedures were approved by the KU Leuven
Ethics Committee (nr. ML1723) and by the National
Privacy Commission’s Sectoral Committee (decision nr.
13.026 of March 19, 2013). The procedures to collect
data by Healthdata.be were approved by the Belgian
Privacy Commission on April 17, 2018.
The protocol for this CRCT was approved by the Ethical
Commission Research UZ/KU Leuven with number
S62753 (May 13, 2019) and number S62753/0001 (March
20, 2020).
Trial registration




A researcher of the Intego network will be obtaining
signed and written informed consent from each collab-
orating GP practice, and we will ensure that each GP
practice is given a full explanation of the protocol in an
information letter.
Data collection
The data collection takes 12 months (see Fig. 1).
The data in the EHR of the Intego practices will be
collected by HealthData through eHealth. This is part of
the basic Intego project. This collection will be a snap-
shot of the EHR, which is used daily by GPs during con-
sultation with patients. The data will be hosted on the
Healthdata.be platform, which is described in more de-
tail elsewhere [22].
Based on this data collection, the GPs will receive an
A&F intervention with feedback reports on 4 different
time points (every 3 months). At these time points, we
will remind the GPs to work on their registration level
of specific parameters or coded diagnoses in the EHR.
Every week, we will collect the data of the same prac-
tices, which is part of the basic Intego project. Then, for
this A&F project, we will evaluate every 3months
whether the extended feedback led to a significant im-
provement in the registration level of the intervention
group compared with the control group. We will analyze
only the data of the practices that signed an informed
consent form.
Power calculation
To measure an improvement in our primary and key
secondary outcome, these are the percentage of regis-
tered DM 2 and CKD diagnoses in the EHR, a power
calculation was performed.
To measure an improvement of 10% points (from 75%
to 85%) in our primary outcome with 80% power, an
alpha of 0.05, a variance inflation factor (VIF) of 21.12
(based on an intra-class correlation (ICC) of 0.103), we
need 56 practices to be included in this CRCT, or 28
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practices in each group (Table 2). To measure an im-
provement of 20% points (from 50% to 70%) in our key
secondary outcome with 80% power, an alpha of 0.05, a
VIF of 9.1, and an ICC of 0.32, we need 68 practices to
be included in this CRCT, or 34 practices in each group
(Table 2). To have enough statistical power to measure
an improvement in both outcomes, 68 practices will be
recruited. The VIF and ICC were calculated based on
historical data from the Intego database and were used
to correct for clustering.
A power calculation for our exploratory secondary
outcomes was not performed.
Analysis
SAS software (SAS Institute Inc., Cary, NC, USA)
and R (R Foundation for Statistical Computing,
Vienna, Austria) will be used for analysis and for the
graphs of the feedback. For this study, data will only
be used on an aggregated level (per GP practice).
Analysis will be performed using the numerator and
denominator of each outcome per GP practice. The
results will be reported according to the Consoli-
dated Standards of Reporting Trials (CONSORT)
[29]. The statistical model will not be adjusted by for
any covariates.
To evaluate and explore the effect of the intervention
on the primary and secondary outcome measures, a lo-
gistic generalized estimating equations (GEE) model will
be used. This model is chosen because it can investigate
the average response of an intervention on a population
level. The effect of the intervention will be presented as
the difference in proportions together with its 95% confi-
dence interval. The GEE model will also be used to esti-
mate the proportion of correctly registered diagnoses/




This cluster randomized controlled trial investigates the
effect of an automated A&F intervention to primarily
improve the level of registration of DM 2 and to second-
arily improve the level of registration of CKD in the
EHR of the GP. Furthermore, the registration of heart
failure, lifestyle parameters, and biometric data in the
EHR of the GP are explored together with 4 EHR-
extractable quality indicators. In this way, this study
aims to improve the data completeness of the EHR, pav-
ing the way for future quality assessments.
By implementing an automated A&F intervention with
the help of the Intego database, this CRCT can form a
basis for investigating future A&F interventions, which is
particularly important for chronic diseases. Chronic dis-
eases such as DM 2 and CKD have a high prevalence,
and the quality of primary care for these conditions
needs improvement [9, 10]. We already developed a set
of EHR-extractable quality indicators for DM 2, CKD,
and heart failure, which can be used in future A&F in-
terventions [27, 28, 30]. In addition, large data repositor-
ies in primary care, which collect routine primary
healthcare data anonymized at the source, can be used
to address many research questions of interest [31]. Ex-
amples of these are the Intego database we are using, the
Dutch NIVEL, and the British Royal College of General
Practitioners’ Research and Surveillance Centre [21, 32,
33]. Using a large database consisting of all EHR files of
the Intego practices creates an opportunity to power fu-
ture studies that can measure small differences in effect
between groups. Because of this, it will be possible to
compare different A&F features on, for example, the
content and delivery of the feedback. After all, recent re-
search indicates the need to compare different A&F in-
terventions with each other instead of comparing A&F
interventions with control conditions [34].
Table 2 Power calculation
Assumed % correct diagnoses Required number
C I Alpha N0 (total) ICC VIF Mean per practice N patients N practices
Primary
Diabetes 0.75 0.85 0.05 500 0.103 21.12 192 10,560 56
Key secondary
CKD 0.50 0.70 0.05 186 0.32 9.1 25 1693 68
Required total number of practices to have at least 80% power for the comparison of two proportions based on a logistic regression model correcting for the
clustering of patients within GP practice. ICC and resulting VIF were obtained from historical data. The alpha level has been set at 5% for the primary endpoint
and also at 0.05 for the key secondary endpoint (following a hierarchical closed testing procedure)
C control group, I intervention, Alpha alpha-level, N0 total number of required diagnoses (patients) based on a χ2-test (hence, ignoring clustering within GP
practices), ICC intra-class correlation, VIF variance inflation factor (taking into account differences in cluster size), Cluster size number of diagnoses per practice,
Mean per practice mean denominator per practice, N patients total number of required diagnoses taking into account the clustering, N practices required total
number of practices. The number of practices is rounded upwards such that an equal number of practices can be allocated to the control and the
intervention group
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The feedback features that are implemented in this
CRCT are the use of benchmarks, the frequency, the
evidence-based aspect, and a low cognitive load of the
feedback. These features are only a few of the 313
theory-informed hypotheses that were suggested as po-
tentially important for improving the effectiveness of
A&F interventions [16]. However, in the case of primary
care, there is evidence that GPs prefer brief feedback in-
terventions and reports with comparisons and best
practice guidelines [35]. With this in mind, the afore-
mentioned features concerning the content and delivery
of the feedback are chosen for this trial and combined
into an action plan. Furthermore, the use of benchmarks
is, according to the recent Clinical Performance Feed-
back Intervention Theory, useful for improving feedback
because it will motivate and compare feedback recipients
[36]. Because the Intego database gathers data from ap-
proximately 400 GPs, it will be possible to benchmark
their results with each other and more specifically with
the mean of the top 10% performers according to the
Achievable Benchmarks of Care method [23]. Finally,
the feedback will be given on four different occasions,
since the frequency of the feedback delivery (more than
once) is already known to be an important factor [14].
Strengths and limitations
One of the strengths of this study is the underlying gen-
eric approach we are implementing for improving the
registration level of two chronic diseases (DM 2 and
CKD) in the EHR of the GP. This generic approach is an
automated A&F intervention that can be adapted for
other diseases and with other features of feedback, so
that facilitating factors of future interventions can be
evaluated and compared. This thus opens up the possi-
bility to step away from two-arm trials (control versus
intervention) in favor of head-to-head trials, as suggested
by other authors [34]. Implementing future interventions
in this manner and using the Intego database as a large
sample size, together with our generic approach, offers
the opportunity to power studies that can measure small
differences in the effectiveness of certain facilitating fac-
tors or features of A&F for improving the quality of pri-
mary care [34].
Our study also has some limitations. Since we are
implementing an automated and EHR-based interven-
tion, potential sources of bias when (re) using data gath-
ered in the EHR need to be considered [31]. However,
the generic aspect of our intervention can potentially as-
sist in resolving some of those problems, such as the
quality of the primary care EHR data. Another limitation
is that if we want to apply automated quality assessment
in the form of A&F for specific diseases, quality indica-
tors that are extractable from the EHR of the GP for
these diseases need to be available.
Trial status
The recruitment for the trial will start in January 2021
and is expected to be completed in June 2021. This
protocol is version 4.0, dated June 7, 2020.
Trial funding
The Intego project is funded by the Flemish Agency
“Zorg en Gezondheid.” This trial did not receive individ-
ual funding. There was no funding for the design of the
study and for the collection, analysis, and interpretation
of the data. There was also no funding for writing the
manuscript.
Conclusion
This CRCT investigates the effectiveness of an auto-
mated A&F intervention in primary care to improve the
data completeness of the EHR. Different features con-
cerning the content and delivery of the feedback will be
implemented and evaluated.
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